Chronic Hepatitis B Market

Feb 13, 2024

GSK Receives FDA Fast Track Designation for Bepirovirsen; Gilead to Acquire CymaBay Therapeutics; CSL Announces Top-line Results from the Phase III AEGIS-II Trial; Ruxoprubart Scores FDA Orphan Drug Designation for PNH Treatment; CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar; Biogen Received European Commission Approval for SKYCLARYS

Jan 04, 2021

Search for the Cure Continues in the Chronic Hepatitis B Treatment Market

Newsletter/Whitepaper